Inogen (INGN)·Q4 2025 Earnings Summary

Inogen Q4 2025 Earnings: First Positive EBITDA Since 2021, Announces $30M Buyback

February 24, 2026 · by Fintool AI Agent

Inogen (NASDAQ: INGN) delivered a significant profitability milestone in Q4 2025, achieving its first positive full-year adjusted EBITDA since 2021. The portable oxygen concentrator maker also announced a $30 million share repurchase program, signaling confidence in its turnaround trajectory. Shares rose ~1.4% during regular trading and climbed to $5.90 (+3.9%) in after-hours, though the stock remains down substantially from its 52-week high of $11.94.

Did Inogen Beat Earnings?

Q4 2025 showed continued improvement in profitability despite modest top-line growth:

The big story: Full-year 2025 adjusted EBITDA turned positive at $2.7M vs negative $9.5M in 2024—the first positive result since 2021 . GAAP net loss improved 37% to $22.7M from $35.9M .

How Did the Stock React?

The stock's muted reaction reflects the mixed quarter: profitability milestones were encouraging, but gross margin compression (-220 bps) and continued U.S. segment weakness tempered enthusiasm. The $30M buyback (~19% of market cap) provides a floor.

What's Driving Revenue?

International sales continue to be the growth engine while U.S. segments struggle:

For FY 2025, international sales surged 18.4% to $138.8M, offsetting a 3.1% decline in U.S. sales and 6.3% decline in U.S. rentals . Units sold increased 20.3% YoY to 189,400 for the full year .

Key drivers:

• International POC demand remains robust, particularly in Europe
• U.S. B2B channel showing strength; DTC channel still optimizing after team restructuring
• Rental revenue pressured by reimbursement mix and lower patient count (49,000 vs 51,000 YoY)

What Did Management Guide?

Q1 2026 guidance reflects "channel mix and lower expected U.S. rentals revenue driven by reimbursement mix and reduced patients on service" .

Context: Prior guidance for FY 2025 was $354-357M with adjusted EBITDA breakeven . Actual FY 2025 revenue came in at $348.7M (slightly below) but EBITDA exceeded expectations at positive $2.7M.

What Changed This Quarter?

Improved:

• ✓ First positive FY adjusted EBITDA since 2021
• ✓ Operating expenses down 13.1% YoY for full year
• ✓ International sales accelerating (+14.8% Q4, +18.4% FY)
• ✓ $30M buyback signals confidence in balance sheet
• ✓ New product launches: Voxi 5 stationary concentrator, Aurora CPAP masks, Simeox airway clearance
• ✓ Yuwell collaboration advancing (China market entry, portfolio expansion)

Deteriorated:

• ✗ Gross margin contracted 220 bps due to channel mix
• ✗ U.S. sales declined 5.1% in Q4, 3.1% for FY
• ✗ Rental patient count down to 49,000 from 51,000
• ✗ DTC channel still in optimization mode

Capital Allocation

Inogen announced a $30 million share repurchase program authorized through December 31, 2027 . At the current ~$156M market cap, this represents roughly 19% of shares outstanding—a meaningful signal of confidence.

Balance sheet position:

• Cash, cash equivalents, marketable securities: $120.9M
• Total debt: $0
• Stockholders' equity: $192.2M

CEO Kevin Smith commented: "This authorization reflects our confidence in Inogen's strategy, progress towards profitability goals, and long-term growth trajectory. With a strong, debt-free balance sheet, we view this program as providing additional flexibility to deploy capital to support continued investment in innovation and portfolio expansion while enhancing shareholder value."

Key Management Quotes

On the profitability milestone:

"In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundamentals of our business. Our disciplined operational efficiency contributed to a substantial year-over-year improvement in adjusted EBITDA, culminating in a positive result for the first time since 2021." — Kevin Smith, CEO

On 2026 outlook:

"Our strong balance sheet with no debt, puts us in a strong position to accelerate innovation, enhance customer engagement, and drive portfolio expansion in 2026 and beyond. We believe these strategic achievements create a solid foundation for future growth and value creation for our shareholders." — Kevin Smith, CEO

Forward Catalysts

1. Yuwell collaboration rollout — Limited U.S. launch in 2025, fuller rollout in 2026; China registration ongoing
2. Simeox commercialization — Airway clearance device in limited market release, reimbursement trials underway
3. Digital health ecosystem — Patient portal launch, connectivity features to drive brand loyalty
4. DTC channel recovery — Expecting more favorable YoY comparisons as restructured team matures

Full Year 2025 Summary

Bottom Line

Inogen's Q4 2025 marks a credible turnaround checkpoint: positive full-year adjusted EBITDA for the first time since 2021, a $30M buyback authorization, and ~6% revenue growth guidance for 2026. The challenges remain clear—U.S. segment weakness, gross margin pressure from channel mix, and a declining rental patient base—but international sales strength and operational discipline are delivering results.

The stock's modest reaction (+1.4% regular, +3.9% after-hours) suggests investors want to see the 2026 trajectory confirm before re-rating. At ~$156M market cap with $121M in cash and no debt, the risk/reward has improved.

---

Data sourced from Inogen Q4 2025 earnings release, 8-K filing, and company presentations.